This gene has long eluded us. The findings support a direct link between DDX53 and autism, which is not only crucial for future clinical genetic testing, but its discovery suggests that the pathway it affects is related to the behavioral traits of autism, opening a whole new area of exploration.
News & Features
Machine Learning Uncovers Osteosarcoma Subtypes, Paving the Way for Personalized Medicine
The breakthrough uses a machine learning technique called Latent Process Decomposition (LPD) to analyze genetic data and categorize patients more accurately.
Large language models can analyze diverse clinical notes on a large scale to reveal the quality of primary care, say researchers after demonstrating how this form of artificial intelligence can track medication side effects among children with attention deficit hyperactivity disorder.
News & Features
Study Suggests Cytomegalovirus Could Contribute to Alzheimer’s Pathology in Certain Individuals
While HCMV typically remains dormant, in some people, the virus may linger in an active state in the gut and travel to the brain via the vagus nerve.
This could open a potential new avenue for therapeutic development.
The University of California San Diego cutting-edge technology provides unprecedented accuracy and flexibility, addressing the challenges of modeling molecular interactions within the intricate, three-dimensional environments of cells.
Genes are more important than previous flu infection in determining the protection a person receives from the seasonal vaccination, in findings that have opened new avenues against future viral pandemics.
A genetic predisposition to dyslexia may be associated with brain structure, research in over 30,000 adults suggests, with the potential involvement of brain networks involving motor coordination, vision, and language.
New findings reveal how macrophages behave differently depending on the time of day, highlighting a potential for time-specific treatments for inflammatory diseases.
The clearance marks a major milestone as Sangamo prepares to launch a Phase I/II clinical trial in mid-2025 to evaluate the safety and efficacy of this novel treatment.